Acadia Pharmaceuticals (ACAD) Free Cash Flow Growth (3y) (2013 - 2026)
Acadia Pharmaceuticals (ACAD) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 31.42% |
| 10 | Acadia Pharmaceuticals | 4.38 Bn | 3.52 Bn | 243.27 Mn | 53.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.32% |
| Dec 31, 2025 | -30.27% |
| Sep 30, 2025 | 369.74% |
| Jun 30, 2025 | 89.92% |
| Mar 31, 2025 | 31.35% |
| Dec 31, 2024 | 55.04% |
| Sep 30, 2024 | 78.66% |
| Jun 30, 2024 | 44.00% |
| Mar 31, 2024 | 35.27% |
| Dec 31, 2023 | 69.80% |
| Sep 30, 2023 | -33.98% |
| Jun 30, 2023 | 30.18% |
| Mar 31, 2023 | 28.92% |
| Dec 31, 2022 | 7.27% |
| Sep 30, 2022 | 66.26% |
| Jun 30, 2022 | 30.09% |
| Mar 31, 2022 | -5.50% |
| Dec 31, 2021 | 16.42% |
| Sep 30, 2021 | 26.68% |
| Jun 30, 2021 | 14.78% |